Results showed that CEA/CD3-bscAbs redirected human T cells to lyse CEA+ tumor cells in vitro and in vivo, and the bscAbs could mediate efficient regression in different tumor cell models, though the available CEA-binding site is under sufficient. This evidence concerns the gene CEACAM5 and neoplasm.